These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 21831969)

  • 21. Glutamic acid decarboxylase (GAD65) autoantibodies in prediction of beta-cell function and remission in recent-onset IDDM after cyclosporin treatment. The Canadian-European Randomized Control Trial Group.
    Petersen JS; Dyrberg T; Karlsen AE; Mølvig J; Michelsen B; Nerup J; Mandrup-Poulsen T
    Diabetes; 1994 Nov; 43(11):1291-6. PubMed ID: 7926302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Triple specificity of ZnT8 autoantibodies in relation to HLA and other islet autoantibodies in childhood and adolescent type 1 diabetes.
    Andersson C; Vaziri-Sani F; Delli A; Lindblad B; Carlsson A; Forsander G; Ludvigsson J; Marcus C; Samuelsson U; Ivarsson S; Lernmark A; Larsson HE;
    Pediatr Diabetes; 2013 Mar; 14(2):97-105. PubMed ID: 22957668
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibody response to islet antigens in anti-CD4/prednisolone immune intervention of type 1 diabetes.
    Kohnert KD; Hehmke B; Keilacker H; Ziegler M; Emmrich F; Laube F; Michaelis D
    Int J Clin Lab Res; 1996; 26(1):55-9. PubMed ID: 8739857
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Genetic risk determines the emergence of diabetes-associated autoantibodies in young children.
    Kupila A; Keskinen P; Simell T; Erkkilä S; Arvilommi P; Korhonen S; Kimpimäki T; Sjöroos M; Ronkainen M; Ilonen J; Knip M; Simell O
    Diabetes; 2002 Mar; 51(3):646-51. PubMed ID: 11872662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
    Pescovitz MD; Greenbaum CJ; Krause-Steinrauf H; Becker DJ; Gitelman SE; Goland R; Gottlieb PA; Marks JB; McGee PF; Moran AM; Raskin P; Rodriguez H; Schatz DA; Wherrett D; Wilson DM; Lachin JM; Skyler JS;
    N Engl J Med; 2009 Nov; 361(22):2143-52. PubMed ID: 19940299
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Types of pediatric diabetes mellitus defined by anti-islet autoimmunity and random C-peptide at diagnosis.
    Redondo MJ; Rodriguez LM; Escalante M; Smith EO; Balasubramanyam A; Haymond MW
    Pediatr Diabetes; 2013 Aug; 14(5):333-40. PubMed ID: 23458188
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Specificity of islet cell autoantibodies and coexistence with other organ specific autoantibodies in type 1 diabetes mellitus.
    Tsirogianni A; Pipi E; Soufleros K
    Autoimmun Rev; 2009 Jul; 8(8):687-91. PubMed ID: 19217947
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined use of autoantibodies (IA-2 autoantibody, GAD autoantibody, insulin autoantibody, cytoplasmic islet cell antibodies) in type 1 diabetes: Combinatorial Islet Autoantibody Workshop.
    Verge CF; Stenger D; Bonifacio E; Colman PG; Pilcher C; Bingley PJ; Eisenbarth GS
    Diabetes; 1998 Dec; 47(12):1857-66. PubMed ID: 9836516
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Islet autoantibodies in cord blood from patients who developed type 1 diabetes mellitus at 15-30 years of age.
    Elfving AM; Lindberg BA; Nyström L; Sundkvist G; Lernmark A; Ivarsson SA;
    Autoimmunity; 2003 Jun; 36(4):227-31. PubMed ID: 14563016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Could ZnT8 antibodies replace ICA, GAD, IA2 and insulin antibodies in the diagnosis of type 1 diabetes?
    Lounici Boudiaf A; Bouziane D; Smara M; Meddour Y; Haffaf EM; Oudjit B; Chaib Mamouzi S; Aouichat Bouguerra S
    Curr Res Transl Med; 2018 Mar; 66(1):1-7. PubMed ID: 29487039
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exposure to exogenous insulin promotes IgG1 and the T-helper 2-associated IgG4 responses to insulin but not to other islet autoantigens.
    Füchtenbusch M; Kredel K; Bonifacio E; Schnell O; Ziegler AG
    Diabetes; 2000 Jun; 49(6):918-25. PubMed ID: 10866043
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mature high-affinity immune responses to (pro)insulin anticipate the autoimmune cascade that leads to type 1 diabetes.
    Achenbach P; Koczwara K; Knopff A; Naserke H; Ziegler AG; Bonifacio E
    J Clin Invest; 2004 Aug; 114(4):589-97. PubMed ID: 15314696
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The three ZNT8 autoantibody variants together improve the diagnostic sensitivity of childhood and adolescent type 1 diabetes.
    Andersson C; Larsson K; Vaziri-Sani F; Lynch K; Carlsson A; Cedervall E; Jönsson B; Neiderud J; Månsson M; Nilsson A; Lernmark A; Elding Larsson H; Ivarsson SA
    Autoimmunity; 2011 Aug; 44(5):394-405. PubMed ID: 21244337
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple chimeric islet autoantigen IA2-ZnT8WR to facilitate islet autoantibody determination.
    Yu L; Liu Y; Miao D; Wenzlau J; Davidson H; Hutton J; Eisenbarth GS
    J Immunol Methods; 2010 Feb; 353(1-2):20-3. PubMed ID: 20035758
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Validity of screening for individuals at risk for type I diabetes by combined analysis of antibodies to recombinant proteins.
    Christie MR; Roll U; Payton MA; Hatfield EC; Ziegler AG
    Diabetes Care; 1997 Jun; 20(6):965-70. PubMed ID: 9167107
    [TBL] [Abstract][Full Text] [Related]  

  • 36. GAD65 autoantibodies increase the predictability but not the sensitivity of islet cell and insulin autoantibodies for developing insulin dependent diabetes mellitus.
    Schott M; Schatz D; Atkinson M; Krischer J; Mehta H; Vold B; Maclaren N
    J Autoimmun; 1994 Dec; 7(6):865-72. PubMed ID: 7888042
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Influence of sex and age at onset on autoantibodies against insulin, GAD65 and IA2 in recent onset type 1 diabetic patients.
    Bilbao JR; Rica I; Vázquez JA; Busturia MA; Castaño L
    Horm Res; 2000; 54(4):181-5. PubMed ID: 11416235
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.
    Orban T; Sosenko JM; Cuthbertson D; Krischer JP; Skyler JS; Jackson R; Yu L; Palmer JP; Schatz D; Eisenbarth G;
    Diabetes Care; 2009 Dec; 32(12):2269-74. PubMed ID: 19741189
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimized autoantibody-based risk assessment in family members. Implications for future intervention trials.
    Bingley PJ; Williams AJ; Gale EA
    Diabetes Care; 1999 Nov; 22(11):1796-801. PubMed ID: 10546010
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-glutamate decarboxylase and other antibodies at the onset of childhood IDDM: a population-based study.
    Verge CF; Howard NJ; Rowley MJ; Mackay IR; Zimmet PZ; Egan M; Hulinska H; Hulinsky I; Silvestrini RA; Kamath S
    Diabetologia; 1994 Nov; 37(11):1113-20. PubMed ID: 7867883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.